ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020

SAN DIEGO—(BUSINESS WIRE)—Jan. 7, 2020—ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical companyfocused on the development and commercialization of innovative medicinesthat address unmet medical needs in central nervous system disorders,today announced that it will present at the 38^th Annual J.P.Morgan Healthcare Conference in San Francisco on Tuesday, January 14,2020, at 10:00 a.m. Pacific Time, followed by a question and answerbreakout session.

A live webcast of ACADIA’s presentation and breakout session will beaccessible on the company’s website, www.acadia-pharm.com,under the investors section and an archived recording will be availableon the website through February 14, 2020.

About ACADIA Pharmaceuticals

ACADIA is a biopharmaceutical company focused on the development andcommercialization of innovative medicines to address unmet medical needsin central nervous system disorders. ACADIA has developed andcommercialized the first and only medicine approved for the treatment ofhallucinations and delusions associated with Parkinson’s diseasepsychosis. ACADIA also has ongoing clinical development efforts inadditional areas with significant unmet need, including dementia-relatedpsychosis, major depressive disorder, the negative symptoms ofschizophrenia, and Rett syndrome. This press release and furtherinformation about ACADIA can be found at: www.acadia-pharm.com.

Source: ACADIA Pharmaceuticals Inc.

Media Contact:

ACADIA Pharmaceuticals Inc.
StephanieFagan
(858) 212-0534
media@acadia-pharm.com

Investor Contact:

ACADIA Pharmaceuticals Inc.
MarkJohnson, CFA
(858) 261-2771
ir@acadia-pharm.com